Giri V.N. Hyatt C. Gomella L.G.

GT for men with prostate cancer: Navigating an expanding new world of genetic evaluation for precision therapy and precision management.

J Clin Oncol. 37: 1455-1459

The historical perspective: sheldon reed and 50 years of genetic counseling.

J Genet Couns. 6: 375-377Uhlmann W.R. Schuette J.L. Yashar B.

A guide to genetic counseling.

2nd edition. Wiley-Blackwell, Hoboken (NJ)Resta R. Biesecker B.B. Bennett R.L. et al.

A new definition of genetic counseling: national society of genetic counselors’ task force report.

J Genet Counsel. 15: 77-83Hyatt C. Russo J. McDougall C.

Genetic counseling perspective of engagement with urology and primary care.

Can J Urol. 26: 52-53Giri V.N. Knudsen K.E. Kelly W.K. et al.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

J Clin Oncol. 38: 2798-2811Hampel H. Bennett R.L. Buchanan A. et al.

A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Genet Med. 17: 70-87Bensend T.A. Veach P.M. Niendorf K.B.

What’s the harm? Genetic counselor perceptions of adverse effects of genetics service provision by non-genetics professionals.

J Genet Couns. 23: 48-63Hampel H. Grubs R.E. Walton C.S. et al.

Genetic counseling practice analysis.

J Genet Couns. 18: 205-216Bjorvatn C. Eide G.E. Hanestad B.R. et al.

Risk perception, worry and satisfaction related to genetic counseling for hereditary cancer.

J Genet Couns. 16: 211-222Bratt O. Damber J.E. Emanuelsson M. et al.

Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer.

Eur J Cancer. 36: 235-241Culver J.O. Brinkerhoff C.D. Clague J. et al.

Variants of uncertain significance in BRCA testing: Evaluation of surgical decisions, risk perception, and cancer distress.

Clin Genet. 84: 464-472Cicero G. DeLuca R. Dorangricchia P. et al.

Risk perception and psychological distress in genetic counselling for hereditary breast and/or ovarian cancer.

J Genet Couns. 26: 999-1007Palmero E.I. Campacci N. Schuler-Faccini L. et al.

Cancer-related worry and risk perception in Brazilian individuals seeking genetic counseling for hereditary breast cancer.

Genet Mol Biol. 43: 1-7Bennett R.L. Steinhaus French K. Resta R.G. et al.

Standardized human pedigree nomenclature: Update and assessment of the recommendations of the National Society of Genetic Counselors.

J Genet Couns. 17: 424-433Riley B.D. Culver J.O. Skrzynia C. et al.

Essential elements of genetic cancer risk assessment, counseling, and testing: Updated recommendations of the National Society of Genetic Counselors.

J Genet Couns. 21: 151-161Balmaña J. Digiovanni L. Gaddam P. et al.

Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing.

J Clin Oncol. 34: 4071-4078Richards S. Aziz N. Bale S. et al.

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Genet Med. 17: 405-423Mersch J. Brown N. Pirzadeh-Miller S. et al.

Prevalence of variant reclassification following hereditary cancer genetic testing.

JAMA. 320: 1266-1274Giri V.N. Obeid E. Gross L. et al.

Inherited Mutations in Males Undergoing Multigene Panel Testing for PCA – emerging implications for personalized prostate cancer genetic evaluation.

J Clin Oncol. https://doi.org/10.1200/PO.16.00039Giri V.N. Obeid E. Hegarty S.E. et al.

Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: implications for genetic counseling.

Prostate. 78: 879-888

Meiser B Psychological impact of genetic testing for cancer susceptibility: an update of the literature.

Psychooncology. 14: 1060-1074Hadley D.W. Ashida S. Jenkins J.F. et al.

Generation after generation: exploring the psychological impact of providing genetic services through a cascading approach.

Genet Med. 12: 808-815

The role of BRCA1 and BRCA2 in prostate cancer.

Asian J Androl. 14 () (): 409-414Giri V.N. Hegarty S.E. Hyatt C. et al.

Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.

Prostate. 79 () (): 333-339

BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.

MedGenMed. 7 () (): 60Nyberg T. Frost D. Barrowdale D. et al.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Eur Urol. 77: 24-35

Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

J Urol. 203: 463-464Castro E. Goh C. Olmos D. et al.

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

J Clin Oncol. 31: 1748-1757Struewing J.P. Hartge P. Wacholder S. et al.

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

N Engl J Med. 336: 1401-1408Ford D. Easton D.F. Stratton M. et al.

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Am J Hum Genet. 62: 676-689Kuchenbaecker K.B. Hopper J.L. Barnes D.R. et al.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

JAMA. 317: 2402-2416Breast Cancer Linkage Consortium

Cancer risks in BRCA2 mutation carriers.

J Natl Cancer Inst. 91: 1310-1316

Fanconi anaemia and cancer: an intricate relationship.

Nat Rev Cancer. 18: 168-185Domchek S.M. Tang J. Stopfer J. et al.

Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.

Cancer Discov. 3: 399-405Sawyer S.L. Tian L. Kähkönen M. et al.

Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.

Cancer Discov. 5: 135-142Ewing C.M. Ray A.M. Lange E.M. et al.

Germline mutations in HOXB13 and prostate-cancer risk.

N Engl J Med. 366: 141-149Laitinen V.H. Wahlfors T. Saaristo L. et al.

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Cancer Epidemiol Biomarkers Prev. 22: 452-460Karlsson R. Aly M. Clements M. et al.

A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.

Eur Urol. 65: 169-176Bauer C.M. Ray A.M. Halstead-Nussloch B.A. et al.

Hereditary prostate cancer as a feature of Lynch Syndrome.

Fam Cancer. 10 () (): 37-42Soravia C. Klift H.M. Brundler M.-A. et al.

Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum.

Am J Med Genet A. 121 () (): 159-162Shan A. Wick M. Persons D.

Microsatellite instability in prostate cancer.

Am J Hum Genet. 55 () ()Duraturo F. Liccardo R. De Rosa M. et al.

Genetics, diagnosis and treatment of Lynch syndrome: Old lessons and current challenges (Review).

Oncol Lett. 17: 3048-3054Lynch H. Snyder C. Shaw T. et al.

Milestones of Lynch syndrome: 1895–2015.

Nat Rev Cancer. 15: 181-194Jenkins M.A. Baglietto L. Dowty J.G. et al.

Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study.

Clin Gastroenterol Hepatol. 4: 489-498Beebe-Dimmer J.L. Kapron A.L. Fraser A.M. et al.

Risk of prostate cancer associated with familial and hereditary cancer syndromes.

J Clin Oncol. 38: 1807-1813Wimmer K. Kratz C.P. Vasen H.F. et al.

Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).

J Med Genet. 51: 355-365Na R. Zheng S.L. Han M. et al.

Germline Mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.

Eur Urol. 71: 740-747Carter H.B. Helfand B. Mamawala M. et al.

Germline Mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer.

Eur Urol. 75: 743-749Mavrou A. Tsangaris G.T. Roma E. et al.

The ATM gene and ataxia telangiectasia.

Anticancer Res. 28: 401-405Seppälä E.H. Ikonen T. Mononen N. et al.

CHEK2 variants associate with hereditary prostate cancer.

Br J Cancer. 89: 1966-1970Cybulski C. Gorski B. Debriak T. et al.

NBS1 is a prostate cancer susceptibility gene.

Cancer Res. 64: 1215-1219Kote-Jarai Z. Jugurnauth S. Mulholland S. et al.

A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.

Br J Cancer. 100: 426-430

Giri VN, Obeid E, Gross L, et al: Inherited mutations in males undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation. JCO Precis Oncol 2017;10.1200/PO.16.00039

Experiences of genetic risk: disclosure and the gendering of responsibility.

Bioethics. 15: 231-247Graves K. Gatammah R. Peshkin B. et al.

BRCA1/2 genetic testing uptake and psychosocial outcomes in men.

Fam Cancer. 1-: 213-223Rauscher E.A. Dean M. Campbell-Salome G.M.

“I Am Uncertain About What My Uncertainty Even Is”: Men’s Uncertainty and Information Management of Their BRCA-Related Cancer Risks.

J Genet Couns. 27: 1417-1427Suttman A. Pilarski R. Agnese D.M. et al.

“Second-class status?” insight into communication patterns and common concerns among men with hereditary breast and ovarian cancer syndrome.

J Genet Couns. 27: 886-893Nicolosi P. Ledet E. Yang S. et al.

Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines.

JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.6760Pritchard C.C. Mateo J. Walsh M.F. et al.

Inherited DNA-repair gene mutations in men with metastatic prostate cancer.

N Engl J Med. 375: 443-453

NCI Staff.

() ()Abida W. Cheng M.L. Armenia J. et al.

Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade.

JAMA Oncol. 5 (): 471-478Edwards S.M. Evans D.G. Hope Q. et al.

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

Br J Cancer. 103: 918Cheng H.H. Sokolova A.O. Schaeffer E.M. et al.

Germline and Somatic Mutations in Prostate Cancer for the Clinician.

J Natl Compr Cancer Netw. 17: 515-521Mandelker D. Zhang L. Kemel Y. et al.

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.

JAMA. 318 (): 825-835

The emerging significance of secondary germline testing in cancer genomics.

J Pathol. 244: 610-615Schrader K.A. Cheng D.T. Joseph V. et al.

Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

JAMA Oncol. 2 (): 104-111Robinson D. Van Allen E.M. Wu Y.M. et al.

Integrative clinical genomics of advanced prostate cancer.

Cell. 161: 1215-1228Cancer Genome Atlas Research Network

The molecular taxonomy of primary prostate cancer.

Cell. 163: 1011-1025Schmidlen T. Schwartz M. DiLoreto K. et al.

Patient assessment of chatbots for the scalable delivery of genetic counseling.

J Genet Couns. 28: 1166-1177Michie S. Bron F. Bobrow M. et al.

Nondirectiveness in genetic counseling: An empirical study.

Am J Hum Genet. 60: 40-47Jamal L. Schupmann W. Berkman B.E.

An ethical framework for genetic counseling in the genomic era.

J Genet Couns. 00: 1-10Schupmann W. Jamal L. Berkman B.E.

Re-examining the ethics of genetic counseling in the genomic era.

Bioethical Inq. 17: 325-335Halbert C.H. Harrison B.W.

Genetic counseling among minority populations in the era of precision medicine.

Am J Hum Genet. 178: 68-74

Intervention and reflection: basic issues in medical ethics.

8th edition. Thomson Higher Education, Belmont (CA)Beauchamp T.L. Childress J.F.

Principles of biomedical ethics.

5th edition. Oxford University Press, New York

Genetic Information Nondiscrimination Act of 2008: Pub.L. 110-233, 122 Stat. 881 (2008).

The health insurance portability and accountability Act (hipaa). U.S. Dept. of Labor, Employee Benefits Security Administrations, Washington, DC

The Patient Protection and Affordable Care Act (PPACA). Pub. L. No. 111-148, 124 Stat. 119. (2010)

The Americans With Disabilities Act of 1990, Pub. L. No. 101-336, 2, 104 Stat. 328. (1991)

Genetics Home Reference. Ataxia-telangiectasia.

() ()

OMIM. Fanconi Anemia, complementation group S; FANCS.

() ()

NCBI. GTR: Genetic Testing Registry. Fanconi Anemia, complementation group D1.

() ()

OMIM. Mismatch Repair Cancer Syndrome; MMRCS.

() ()